Le Lézard
Classified in: Health
Subject: SVY

Global Diagnostic Imaging Partnering Deals Directory 2014-2020: Company A-Z, Stage of Development at Signing, Deal Type, and Therapy Focus


DUBLIN, Oct. 1, 2020 /PRNewswire/ -- The "Global Diagnostic Imaging Partnering Terms and Agreements 2014 to 2020" report has been added to ResearchAndMarkets.com's offering.

Research and Markets Logo

The Global Diagnostic Imaging Partnering Terms and Agreements 2014 to 2020 report provides comprehensive understanding and unprecedented access to the diagnostic imaging partnering agreements entered into by the worlds leading healthcare companies.

This report provides an overview of diagnostic imaging dealmaking, the common clauses, rights and options in the partnering agreement, and also a comprehensive review of deals signed in since 2014.

This report provides a comprehensive and detailed review of all diagnostic imaging deals announced since 2014. The comprehensive agreements chapter is organized by company A-Z, stage of development at signing, deal type, and therapy focus. Each deal title links via Weblink to an online version of the actual deal and alliances database, providing easy access to each deal on demand. Where available, the full deal contract document is also provided and indicated by a document symbol.

Contract documents provide unsurpassed access to the detail of a deal normally announced in brief summary through a press release. Detailed analysis of a contract allow better understanding of the terms agreed between the parties, and importantly the basis under which monies and licensing rights are exchanged.

Key benefits

Global Diagnostic Imaging Partnering Terms and Agreements provides the reader with the following key benefits:

Available contracts are listed by:

Key Topics Covered:

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in Diagnostic Imaging dealmaking
2.1. Introduction
2.2. Diagnostic Imaging partnering over the years
2.3. Most active Diagnostic Imaging dealmakers
2.4. Diagnostic Imaging partnering by deal type
2.5. Diagnostic Imaging partnering by therapy area
2.6. Deal terms for Diagnostic Imaging partnering
2.6.1 Diagnostic Imaging partnering headline values
2.6.2 Diagnostic Imaging deal upfront payments
2.6.3 Diagnostic Imaging deal milestone payments
2.6.4 Diagnostic Imaging royalty rates

Chapter 3 - Leading Diagnostic Imaging deals
3.1. Introduction
3.2. Top Diagnostic Imaging deals by value

Chapter 4 - Most active Diagnostic Imaging dealmakers
4.1. Introduction
4.2. Most active Diagnostic Imaging dealmakers
4.3. Most active Diagnostic Imaging partnering company profiles

Chapter 5 - Diagnostic Imaging contracts dealmaking directory
5.1. Introduction
5.2. Diagnostic Imaging contracts dealmaking directory

Chapter 6 - Diagnostic Imaging dealmaking by technology type

Chapter 7 - Partnering resource center
7.1. Online partnering
7.2. Partnering events
7.3. Further reading on dealmaking

Appendices
Appendix 1 - Diagnostic Imaging deals by company A-Z
Appendix 2 - Diagnostic Imaging deals by stage of development
Discovery
Preclinical
Phase I
Phase II
Phase III
Regulatory
Marketed
Formulation
Appendix 3 - Diagnostic Imaging deals by deal type
Asset purchase
Bigpharma outlicensing
Co-development
Collaborative R&D
Co-market
Co-promotion
CRADA
Cross-licensing
Development
Distribution
Equity purchase
Evaluation
Grant
Joint venture
Licensing
Litigation
Manufacturing
Manufacturing - OEM
Marketing
Option
Promotion
Research
Settlement
Spin out
Sub-license
Supply
Technology transfer
Termination
Appendix 4 - Diagnostic Imaging deals by therapy area
Breast
Cardiovascular
Central Nervous System
Dental
Dermatology
Gastrointestinal
Genetic disorders
Genitourinary
Gynaecology
Hematology
Hospital care
Immunology
Infectives
Musculoskeletal
Obstetrics
Oncology
Ophthalmics
Orphan disease
Pediatrics
Psychiatry
Respiratory
Appendix 5 - Deal type definitions
 
For more information about this report visit https://www.researchandmarkets.com/r/72jm9a

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716



SOURCE Research and Markets


These press releases may also interest you

at 09:05
Quantum Health, the leading consumer healthcare navigation and care coordination company, announced today the launch of its new end-to-end care management solution, Premier Oncology, tailored for employers and their members diagnosed with cancer....

at 09:05
United Therapeutics Corporation , a public benefit corporation, today announced the world's first successful transplant of a UThymoKidneytm, which the company produced, into a living person on April 12, 2024. This transplant represents several...

at 09:05
-- Helius Medical and Shepherd Center partner on a study that aims at rehabilitating walking mobility in people recovering from stroke ---- Shepherd Center, a top neurorehabilitation hospital, is the third site in Helius' U.S. registrational program...

at 09:03
Truth Initiative, the organization behind truth®, the nationally recognized, proven-effective youth tobacco and opioid prevention public education campaigns, and EVERFI® from Blackbaud®, the leader in powering...

at 09:02
3X4 Genetics, leader in the field of genetics-based health, announced today partnerships with Next Health and Forum Health, LLC to serve as the healthcare companies' preferred genetic screening provider. Forum Health, the nationwide network of...

at 09:00
May is Multiple Sclerosis (MS) Awareness Month and MS Canada invites Canadians to join the MS community and navigate MS together. At MS Canada, we work to educate people on the impact of MS in our country and support people living with MS through...



News published on and distributed by: